Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 52, Issue 10, Pages 1573-1579Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.111.092874
Keywords
PD153035; PET; EGFR; molecular imaging; NSCLC
Funding
- National High Technology Research and Development Program of China [2007 AA02Z437]
- National Natural Science Foundation [30870748]
Ask authors/readers for more resources
Outcomes are suboptimal when molecularly targeted therapies are used in patient populations unselected for the molecular target. This pilot study examines the correlation of PET using C-11-labeled 4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline (C-11-PD153035), an imaging biomarker of epidermal growth factor receptor (EGFR), with outcomes in patients with non-small cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor erlotinib. Methods: Patients with advanced chemotherapy-refractory NSCLC were prospectively enrolled on a trial of erlotinib at a dose of 150 mg daily and imaged by C-11-PD153035 PET/CT at baseline, after 1-2 wk, and after 6 wk from the start of treatment. Overall survival and progression-free survival (OS and PFS, respectively) times were correlated with the C-11-PD153035 standardized uptake value (SUV) at each of the imaging times. Results: Twenty-one patients were enrolled. Follow-up to progression was complete in all patients and to death in 18 of 21. By Cox regression analysis, baseline maximum SUV correlated strongly with OS and PFS (hazard ratio = 0.40, P = 0.002, and hazard ratio = 0.044, P < 0.001, respectively) independent of histology. Patients with higher maximum SUV (>= median) survived more than twice as long as patients with lower maximum SUV (median OS = 11.4 vs. 4.6 mo, P = 0.002; PFS = 4.4 vs. 1.8 mo, P < 0.001). However, C-11-PD153035 uptake on follow-up scans was less well correlated with survival. Conclusion: Our preliminary results suggest C-11-PD153035 PET/CT may be a noninvasive and rapid method for identifying patients with refractory advanced NSCLC of adenocarcinoma or squamous histology likely to respond to the EGFR tyrosine kinase inhibitor but not for monitoring treatment response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available